Ann: CEO's address to AGM , page-14

I went to the AGM, had to leave a little early though.

Basically I was impressed by management -- they know their stuff and have realistic goals for the big task ahead but they seem very confident. They have an appreciation for shareholder money, sure biotech investing is never without risk and humans are prone to error, but the technology has a lot of history behind it and this current CEO is not a side kick executive just trying to ride a shareprice gain. He comes from a family line of medical military doctors and has dedicated his time to making this stuff work.

In terms of patient ramp up being slow, they are working on alternatives. They said the competition is facing the exact same thing. Looking for low cost alternatives means they trust in the technology and want to get it going. I would rather hear it now in person than have it suddenly blurted out during an ASX announcement.

Overall, I'm going to keep my stock and wait till this company progresses through its hurdles. Am impressed by management and the honesty. Good luck to holders. A lot of the technical stuff flew over my head, not being a biotech wiz, but I have met a lot of company managers over the years and the people running the company are usually a good indicator of future success. Time will tell and I'm willing to wait. DYOR please.